Table 1.
Demographic and Clinical Characteristics of Hematopoietic Cell Transplantation Survivors and Siblings
| Characteristic | Survivors (N=1040) | Siblings (n=309) | P value |
|---|---|---|---|
| Age at study participation – year | |||
| Medan (±SD) | 43.8 (12.0) | 45.2 (11.8) | 0.03 |
| Range | 18.3–73.0 | 19.3–78.7 | |
| Gender – no. (%) | |||
| Female | 456 (43.8%) | 196 (63.4%) | <0.01 |
| Race – no. (%) | |||
| Non-Hispanic White | 801 (77.0%) | 270 (87.4%) | <0.01 |
| Education – no. (%) | |||
| <High school | 218 (21.0%) | 38 (12.3%) | |
| High school/Some college or training | 369 (35.5%) | 97 (31.4%) | <0.01 |
| College graduate | 452 (43.5%) | 174 (56.3%) | |
| Marital status – no. (%) | |||
| Married | 681 (65.5%) | 242 (78.3%) | <0.01 |
| Household income - no. (%)* | |||
| >$60,000/yr | 430 (44.4%) | 189 (64.3%) | |
| $20–60,000/yr | 383 (39.6%) | 93 (31.6%) | <0.01 |
| <$20,000/yr | 155 (16.0%) | 12 (4.1%) | |
| Health insurance - no. (%) | |||
| Yes | 938 (90.2%) | 291 (94.2%) | 0.03 |
| Age at HCT – year | |||
| Median (±SD) | 34.3 | NA | |
| Range | 0.4–68.6 | NA | |
| Interval between HCT and study – year | |||
| Median (±SD) | 7.4 | NA | |
| Range | 2.0–27.7 | NA | |
| Primary cancer diagnosis – no. (%) | |||
| Chronic myeloid leukemia | 249 (23.9%) | NA | |
| Acute myeloid leukemia | 255 (24.5%) | NA | |
| Hodgkin lymphoma | 92 (8.8%) | NA | |
| Non-Hodgkin lymphoma | 208 (20.0%) | NA | |
| Acute lymphoblastic leukemia | 106 (10.2%) | NA | |
| Others | 130 (12.5%) | NA | |
| Stem cell donor - no. (%) | |||
| Autologous HCT | 444 (42.7%) | NA | |
| Allogeneic donor | 596 (57.3%) | NA | |
| Chronic GvHD - no. (%) | |||
| Yes | 324 (31.2%) | NA | |
| Risk of Relapse at HCT - no. (%) | |||
| Standard risk | 676 (65.0%) | NA | |
| High risk | 364 (35.0%) | NA | |
| Conditioning regimen - no. (%) | |||
| Chemotherapy | 225 (21.6%) | NA | |
| Chemotherapy + TBI | 815 (78.4%) | NA | |
*
Information available for 968 Survivors, 294 Siblings